(Not necessarily addressed to you, Doctor, but part of general discussion)
I suspect that there may be two or three or more elements working at cross-purposes here.
First is that CYPB has virtually no institutional following, beyond our loyal friends at Aries. For months on end, CYPB's MFI has followed price with a correlation near 1.00 ... implying that there is no secret buying in larger volume transactions which are hidden by the "noise" of small volume transactions. Or ... the main buyers and sellers are the small retail people like me, and have been for a long time.
Second is that CYPB, in its earlier incarnation, apparently had a pretty bad reputation with analysts. Once burned, twice shy. Drs. Kranzler and Blank (CEO and Pres) were brought in specifically to clean up that mess ... and we see that new-found caution and straightforwardness at every turn now.
Third is that this is a device, and not a drug. While many consider this a plus, those who are looking for the latest in sexy "compounds" are not likely to be enthused by a "dumb ol' filter" which has been around for a long time.
Lastly, I'm sure that some analysts would like to know why the Prosorba column works.
Whatever the reason, the prolonged lack of public bandwagon effect permits us to gloat smugly that we know it better and that we are smarter and that we are in on the ground floor. Frankly I hope we are right ... but the possibility that we are not right helps me keep my portfolio well-balanced <grin>.
JSb. |
